Effectiveness of Clindamycin and Intravenous Immunoglobulin, and Risk of Disease in Contacts, in Invasive Group A Streptococcal Infections
Jonathan R Carapetis, Peter Jacoby, Kylie Carville, Seong-Jin Joel Ang, Nigel Curtis, Ross Andrews
CLINICAL INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2014
BACKGROUND: The use of clindamycin and intravenous immunoglobulin (IVIG) in treatment of invasive group A streptococcal (iGAS) infection, and the need for prophylactic antibiotics in close contacts, remains contentious. Controlled trials are unlikely to be conducted, so prospective, observational studies provide the best data to inform practice. METHODS: We conducted population-based, prospective, active surveillance of iGAS infections throughout the state of Victoria, Australia (population 4.9 million), from March 2002 through August 2004. RESULTS: Eighty-four cases of severe iGAS infection (streptococcal toxic shock syndrome, necrotizing fasciitis, septic shock, or GAS cellulitis with shoc..View full abstract
Awarded by Australian National Health and Medical Research Council
This study was supported by a grant from the Australian National Health and Medical Research Council (grant number 216214).